Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: A WHO grade III neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and anaplastic glial cells. The anaplastic changes in the glial component and high MIB-1 and TP53 labeling indices may indicate aggressive behavior. However, the correlation of histological anaplasia with clinical outcome is inconsistent. (Adapted from WHO) 
Anaplastic gangliogliomas most frequently harbor alterations in BRAF, KMT2A, ERCC2, CARD11, and ZMIZ1 .
BRAF V600E, BRAF Mutation, BRAF Exon 15 Mutation, BRAF Codon 600 Missense, and KMT2A Mutation are the most common alterations in anaplastic ganglioglioma .
There is 1 clinical trial for anaplastic ganglioglioma, of which 1 is open and 0 are completed or closed. Of the trial that contains anaplastic ganglioglioma as an inclusion criterion, 1 is phase 2 (1 open).
BRAF is the most frequent gene inclusion criterion for anaplastic ganglioglioma clinical trials .
Dabrafenib, radiation therapy, and trametinib are the most common interventions in anaplastic ganglioglioma clinical trials.
Significant Genes in Anaplastic Ganglioglioma
BRAF is altered in 40.0% of anaplastic ganglioglioma patients .
BRAF is an inclusion eligibility criterion in 1 clinical trial for anaplastic ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and anaplastic ganglioglioma as inclusion criteria, 1 is phase 2 (1 open) .
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.